VJOncology is committed to improving our service to you

ESMO 2020 | Standard-dose vs. high-dose thoracic radiotherapy in limited stage SCLC

VJOncology is committed to improving our service to you

Bjørn H Grønberg

Bjørn H Grønberg, MD, PhD, NTNU, Norwegian University of Science and Technology, and St. Olav’s Hospital, Trondheim University Hospital, Trondheim, Norway, outlines patient-reported outcomes from a randomized Phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small cell lung cancer (SCLC). Dr Grønberg discusses the results of quality-of-life endpoints evaluated in this study, including dyspnea, dysphagia and fiscal burdens. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter